Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 10/20 | 0.38 |
| ▸ | CETP | P11597 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1518498 | 0.82 | REN (0.43) | HTR2ANR1H4HSD11B1 | |
| SCHEMBL661553 | 0.82 | REN (0.38) | HTR2ANR1H4KDM1AHDAC8HDAC6 | |
| SCHEMBL1751809 | 0.81 | REN (0.45) | — | |
| SCHEMBL1074676 | 0.77 | REN (0.38) | NR1H4KDM1AHDAC8HDAC6HSD11B1 | |
| SCHEMBL1072457 | 0.75 | REN (0.45) | HTR2A | |
| SCHEMBL24619322 | 0.74 | HTR2A (0.43) | HTR2ACETPKDM1AHDAC8HDAC6 | |
| SCHEMBL29924845 | 0.74 | HTR2A (0.43) | HTR2ACETPKDM1AHDAC8HDAC6 | |
| SCHEMBL24619325 | 0.74 | HTR2A (0.42) | HTR2ANR1H4HSD11B1 | |
| SCHEMBL24619382 | 0.74 | KDM1A (0.43) | HTR2ACETPNR1H4KDM1AHDAC8 | |
| SCHEMBL24619710 | 0.74 | NR1H4 (0.42) | HTR2ACETPNR1H4KDM1AHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2274295-B1 | 3, 4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-08-05 | — | — | EP | disclosed |
| US-8889714-B2 | 3,4-substituted piperidine derivatives as renin inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-11-18 | — | — | US | disclosed |
| US-20110152316-A1 | 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2011-06-23 | — | — | US | disclosed |
| EP-2300453-A1 | 3, 4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2011-03-30 | — | — | EP | disclosed |
| US-20110053940-A1 | 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2011-03-03 | — | — | US | disclosed |
| EP-2274295-A1 | 3, 4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009140769-A1 | 3, 4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009135299-A1 | 3, 4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053940-A1 | 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | REN, ACE, ACE2 | HTR2A 3038/4885CETP 2525/4885RIPK1 3179/4885 |
| US-20110152316-A1 | 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | REN, ACE, AGTR1 | HTR2A 2716/4885CETP 3032/4885RIPK1 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.